Esketamine clinical trials: reply to Maju et al.
Chiara Gastaldon, D. Papola, G. Ostuzzi, Corrado Barbui
Epidemiology and Psychiatric Sciences 2020 DOI: 10.1017/s204579602000027x (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | Esketamine |
| Key points | The authors argue for critically examining the evidence base needed to obtain regulatory approval for esketamine, in reply to Maju et al.'s clarifications about esketamine clinical trial data and the debate following its marketing authorization. The text does not state specific findings or conclusions beyond this framing. |
Abstract
Abstract Maju et al. provided clarifications on important and controversial issues related to esketamine clinical trial data, in response to a vivid debate triggered by the marketing authorisation recently granted by this new medicine. In this commentary, we reply to their comments attempting to critically discuss the evidence base needed to obtain regulatory approval.
Citations in the library
Cited by 2
- Virtual Reality as an Adjunct to Ketamine Infusion Therapy Increases Patient Satisfaction in the Management of Chronic Pain and Depression: A Retrospective Pilot Study Journal of Behavioral and Brain Science 2023
- Effects of Ketamine and Esketamine on Cognitive Functions in Treatment-Resistant Depression Psikiyatride Güncel Yaklaşımlar September 30, 2025
Cites 5
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study American Journal of Psychiatry May 21, 2019
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression JAMA Psychiatry June 5, 2019
- Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) The International Journal of Neuropsychopharmacology July 9, 2019
- Esketamine for treatment resistant depression: a trick of smoke and mirrors? Epidemiology and Psychiatric Sciences 2020
- Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review. CNS Drugs May 2018